Shun C T, Wu M S, Lin J T, Chen S Y, Wang H P, Lee W J, Wang T H, Chuang S M
Department of Pathology, College of Medicine, National Taiwan University, Taipei.
Hepatogastroenterology. 1997 Mar-Apr;44(14):604-9.
BACKGROUND/AIMS: Conflicting results concerning the relationships between abnormal expression of p53 and c-erbB-2 and biologic behavior of gastric cancer are noted. Therefore, overexpression of p53 and c-erbB-2 in relation to the following aspects of gastric cancer: tumor histopathology, Helicobacter pylori infection, and prognosis are explored.
Expression of p53 and c-erbB-2 by immunohistochemistry was correlated with histopathology, H. pylori infection and prognosis of gastric cancer in 112 patients.
Positive p53 staining was found in 61 (54.5%) of 112 tumors examined. There was no association of p53 expression with sex, age, lymph node metastasis, H. pylori infection or prognosis. A significantly higher frequency of p53-positive staining was observed in advanced (60.7%), intestinal (69.8%) and cardia (76.5%) than in early (30.4%, p < 0.01), diffuse (34.7%, p < 0.01) and noncardia (50.5%, p < 0.05) carcinoma, respectively. Expression of c-erbB-2 was found in 34 cases (30.3%), and was not related to sex, age, H. pylori infection and tumor location. Tumors with positive c-erbB-2 staining appeared to behave more aggressively in view of higher rates of nodal metastasis (38.0% vs 17.1%, p < 0.05), advanced stage (37.1% vs 4.3%, p < 0.01) and poor mean survival (p < 0.01). Patients with intestinal type tumors also had a significantly higher rate of c-erbB-2 expression than those with diffuse tumors (39.7% vs 18.4%, p < 0.01).
Our results indicate that immunohistochemical expressions of p53 and c-erbB-2 are significantly associated with some histopathological phenotypes. Genetic alterations of c-erbB-2 or p53 may not be affected by H. pylori infection. C-erbB-2 expression may be used as a marker for identifying more aggressive gastric cancer for designing further therapy.
背景/目的：关于p53和c-erbB-2异常表达与胃癌生物学行为之间的关系，存在相互矛盾的结果。因此，探讨p53和c-erbB-2的过表达与胃癌以下方面的关系：肿瘤组织病理学、幽门螺杆菌感染及预后。
采用免疫组织化学方法检测112例胃癌患者p53和c-erbB-2的表达，并分析其与组织病理学、幽门螺杆菌感染及预后的关系。
112例肿瘤中，61例（54.5%）p53染色呈阳性。p53表达与性别、年龄、淋巴结转移、幽门螺杆菌感染及预后无关。p53阳性染色在进展期（60.7%）、肠型（69.8%）和贲门癌（76.5%）中的发生率显著高于早期（30.4%，p<0.01）、弥漫型（34.7%，p<0.01）和非贲门癌（50.5%，p<0.05）。34例（30.3%）检测到c-erbB-2表达，其与性别、年龄、幽门螺杆菌感染及肿瘤部位无关。c-erbB-2染色阳性的肿瘤在淋巴结转移率（38.0%对17.1%，p<0.05）、进展期（37.1%对4.3%，p<0.01）及平均生存期较差（p<0.01）方面表现出更具侵袭性的行为。肠型肿瘤患者的c-erbB-2表达率也显著高于弥漫型肿瘤患者（39.7%对18.4%，p<0.01）。
我们的结果表明，p53和c-erbB-2的免疫组织化学表达与某些组织病理学表型显著相关。c-erbB-2或p53的基因改变可能不受幽门螺杆菌感染的影响。c-erbB-2表达可作为识别更具侵袭性胃癌的标志物，用于设计进一步的治疗方案。
